GLOAS Limited
Frontier in revolutionizing the discovery and development of novel drugs and therapeutics for neonatal liver diseases
 |  |  |  |
|---|---|---|---|
 |  |  |  |
 |  |
Our Story
Mini-organ: making personalized medicine possible
Gut Liver Organoid Applied Sciences (GLOAS) Limited is co-founded by clinicians and scientists stationed in the University of Hong Kong (HKU) and is a stem cell and organoid biotechnology startup company headquartered in Hong Kong. Our clinicians and scientists have pioneered a range of state-of-the-art organoid technologies, with a strong proprietary Intellectual Property (IP) portfolio. Our scientific team has constructed the world’s first human Biliary Atresia-derived liver organoid model from patient.
What We Do
At GLOAS, we believe that our solutions will soon become one of the biggest segments in the industry. We’ve only just started, but we already know that every product we build requires hard-earned skills, dedication and a daring attitude. Take advantage of this cutting-edge technology, GLOAS aims at aspires revolutionizing:
- Pre-clinical drug discovery, hepato- and gastrointestinal toxicity screening and liver / gut disease modeling;
- Post-discovery, clinical development of novel therapeutics; and
- Pre-clinical and clinical development of cell-based liver & gut regenerative therapies.
